CVRx launches registry to track hypertension-device patients

Minnesota's CVRx is starting up a post-market hypertension registry in Europe to keep tabs on patients who received its hypertension-treating Barostim Neo device. The company expects to enroll about 500 patients, and it will monitor safety data on the CE-marked device, currently available Germany, Italy, the Netherlands, Switzerland and Austria. And while the company made no mention of it, it's safe to assume CVRx is gathering the extra safety data to file for approval in other countries and expand its market share in the en-vogue sector of hypertension techs. Release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.